Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Buys $24,750.00 in Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel acquired 1,800 shares of the stock in a transaction dated Tuesday, January 7th. The stock was bought at an average price of $13.75 per share, for a total transaction of $24,750.00. Following the completion of the purchase, the chief executive officer now owns 5,550,002 shares in the company, valued at approximately $76,312,527.50. This trade represents a 0.03 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

Snehal Patel also recently made the following trade(s):

• On Thursday, January 2nd, Snehal Patel bought 2,000 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $11.97 per share, with a total value of $23,940.00.
• On Monday, December 30th, Snehal Patel acquired 3,200 shares of Greenwich LifeSciences stock. The stock was acquired at an average price of $11.12 per share, with a total value of $35,584.00.

Greenwich LifeSciences Price Performance

Shares of NASDAQ GLSI opened at $13.81 on Wednesday. The company’s 50 day simple moving average is $13.18 and its 200 day simple moving average is $14.14. Greenwich LifeSciences, Inc. has a fifty-two week low of $8.00 and a fifty-two week high of $21.44. The firm has a market capitalization of $181.53 million, a P/E ratio of -17.26 and a beta of 1.66.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in GLSI. Garden State Investment Advisory Services LLC bought a new stake in Greenwich LifeSciences in the third quarter valued at about $253,000. Barclays PLC increased its stake in shares of Greenwich LifeSciences by 323.3% in the 3rd quarter. Barclays PLC now owns 8,560 shares of the company’s stock valued at $123,000 after acquiring an additional 6,538 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Greenwich LifeSciences by 4.6% in the 3rd quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock valued at $1,919,000 after acquiring an additional 5,861 shares during the period. State Street Corp grew its holdings in Greenwich LifeSciences by 4.4% during the third quarter. State Street Corp now owns 71,408 shares of the company’s stock valued at $1,026,000 after purchasing an additional 3,005 shares during the period. Finally, Rhumbline Advisers bought a new stake in Greenwich LifeSciences in the second quarter valued at approximately $117,000. Institutional investors and hedge funds own 4.16% of the company’s stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.